Nasdaq:US$39.28 (-1.11) | HKEX:HK$60.55 (-6.40) | AIM:£5.37 (-0.28)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China,  strive to create differentiated novel oncology and immunology treatments with global potential.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.